Who Is Signos Best For? Ideal Patient Profile, Evidence, and Alternatives

What Signos Actually Does

Signos is a subscription service that ships a prescription-grade continuous glucose monitor to your door and pairs it with a smartphone app. The app logs glucose responses to meals, exercise, and sleep, then generates personalized recommendations meant to reduce glucose spikes. The premise is simple: if you can see how your body reacts to specific foods in real time, you will make different choices.

The CGM Hardware

The sensors Signos uses (typically the Dexcom G7 or Abbott Libre 3) are FDA-cleared for glucose monitoring [1]. These are the same devices prescribed to patients with type 1 and type 2 diabetes. A filament sits just under the skin and measures interstitial glucose every 1 to 5 minutes, transmitting readings to a paired phone.

The Software Layer

Signos adds a proprietary algorithm on top of the raw glucose data. It scores meals, assigns a metabolic "zone," and prompts users to walk or adjust eating timing when glucose exceeds a personalized threshold. The company has not published peer-reviewed validation of its scoring algorithm as of May 2026.

This distinction matters. The CGM sensor is a validated medical device. The Signos interpretation layer is a wellness product.

The Ideal Patient Profile for CGM-Based Weight Loss

Not everyone benefits equally from wearing a glucose monitor. Research on CGM use in non-diabetic populations is still limited, but a pattern has emerged from the available data.

Prediabetes and Insulin Resistance

The strongest candidates are adults with prediabetes. The CDC estimates that 97.6 million U.S. Adults aged 18 and older have prediabetes, and more than 80% of them do not know it [2]. A 2023 systematic review in Diabetes Technology & Therapeutics found that CGM use in prediabetic adults improved time-in-range glucose metrics and was associated with a 0.3% mean reduction in HbA1c over 12 weeks compared to controls using standard dietary advice alone [3].

The American Diabetes Association's 2024 Standards of Care note that "CGM may be considered in people with prediabetes or those at risk for type 2 diabetes to identify glycemic patterns that inform lifestyle modification" [4]. This is a conditional, not universal, recommendation.

BMI 27 and Above with Metabolic Risk Factors

A 2022 randomized trial published in JAMA Network Open (N=164) studied CGM-guided dietary intervention in adults with a BMI between 27 and 40. Participants using real-time CGM data lost 3.26 kg more than the control group over 12 weeks, with the CGM group showing greater reductions in postprandial glucose excursions [5]. The effect was most pronounced in participants with baseline fasting glucose above 100 mg/dL.

Adults at a healthy weight with normal fasting glucose (<100 mg/dL) showed minimal glucose variability in an observational study of 153 non-diabetic participants wearing CGMs for 10 days. Their time-in-range (70-140 mg/dL) exceeded 96% [6]. There simply is not enough glucose volatility in this group to create actionable behavioral feedback.

Failed Calorie-Counting Approaches

People who have tried and abandoned calorie-tracking apps may find CGM data more motivating because the feedback is immediate and biological rather than numerical and abstract. A qualitative analysis in the Journal of Medical Internet Research found that CGM users described glucose spikes as "more real" than calorie counts, with 72% of participants reporting sustained dietary changes at 6 months compared to 41% in a food-diary control group [7].

Who Should Not Use Signos

Some populations are poor candidates for this service. Identifying them is as important as identifying the ideal user.

Healthy-Weight Adults with Normal Glucose Metabolism

If your fasting glucose is below 95 mg/dL and your HbA1c is under 5.4%, a CGM will likely show a flat, unremarkable line for most of the day. Dr. Roy Taylor, professor of medicine at Newcastle University, has noted that "continuous glucose monitoring in metabolically healthy individuals generates data without clinical meaning, creating anxiety where none is warranted" [8].

People with Active Eating Disorders

Real-time biometric feedback can intensify obsessive food monitoring. The National Eating Disorders Association has cautioned against wearable nutrition trackers in individuals with a history of anorexia nervosa or orthorexia [9]. Signos does not screen for eating disorder history during its onboarding flow.

Those Seeking a Replacement for GLP-1 Therapy

CGM-based behavioral nudging produces modest weight loss (typically 2-4% of body weight over 12 weeks in studies). By comparison, semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo [10]. Tirzepatide 15 mg achieved 22.5% in SURMOUNT-1 (N=2,539) [11]. CGM coaching is not pharmacotherapy and should not be positioned as equivalent.

Is Signos Legit? Evaluating the Evidence

"Legit" depends on what you are evaluating. The hardware is real. The concept has biological plausibility. The evidence for the specific Signos platform is thin.

What Is Validated

CGM sensors are FDA-cleared and well-validated for glucose accuracy (mean absolute relative difference of 8.2% for Dexcom G7) [12]. The biological principle that postprandial glucose spikes vary by individual and can be modified through food selection is supported by a landmark 2015 Cell study (N=800) from the Weizmann Institute [13].

What Is Not Validated

Signos has not published randomized controlled trials testing its specific platform against a control group. The company cites internal data on its website, but internal data without peer review does not meet the evidence threshold for clinical claims. This is a gap shared by most CGM wellness companies (Levels, Nutrisense, Veri), not a problem unique to Signos.

Regulatory Status

The Signos app is not FDA-cleared or approved as a medical device or digital therapeutic. It operates as a general wellness product. The CGM sensors it uses are FDA-cleared, but the combination of sensor plus algorithm plus coaching does not have its own regulatory clearance [1].

Signos Cost Breakdown

Signos operates on a subscription model. Prices have fluctuated since the company's launch, but as of early 2026, the typical pricing structure is:

• One-month plan: approximately $399/month
• Three-month plan: approximately $299/month
• Six-month plan: approximately $199/month

These prices include the CGM sensors (usually two per month), app access, and algorithmic coaching. Insurance does not typically cover CGM sensors prescribed for weight management rather than diabetes [14]. Some users with prediabetes diagnoses (ICD-10 R73.03) have reported partial reimbursement through HSA or FSA accounts.

Hidden Cost Considerations

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that "the cost-effectiveness of continuous glucose monitoring for weight management in non-diabetic populations has not been established" [15]. At $199-$399 per month, a six-month Signos subscription costs $1,194 to $2,394. For context, compounded semaglutide through telehealth platforms has ranged from $150 to $500 per month, and unlike CGM coaching, GLP-1 agonists have Phase III trial data supporting 10-20% body weight reductions.

Signos vs. Alternatives

Several competitors offer similar CGM-plus-app packages. The differences are in software features, clinical support, and pricing.

Nutrisense

Nutrisense pairs CGM data with access to registered dietitians for one-on-one consultations. Plans start around $225/month for a three-month commitment. The dietitian access is a differentiator. A 2024 pilot study (N=48) associated Nutrisense use with a 2.1% body weight reduction over 8 weeks, though the study lacked a control group [16].

Levels

Levels emphasizes metabolic fitness scoring and zone-based eating guidance. It paused direct-to-consumer sales in 2024 to refocus on employer wellness programs but has resumed individual subscriptions. Pricing is comparable to Signos at approximately $199/month on longer plans.

Veri

Veri is a European-origin platform available in the U.S. That focuses on meal scoring with a simpler interface. Plans start around $185/month. Like Signos, Veri has not published peer-reviewed clinical trials on its specific platform.

GLP-1 Telehealth Platforms

For individuals whose primary goal is significant weight loss (more than 5% body weight), GLP-1 agonist prescribing platforms (Ro, Hims, HealthRX) offer a pharmacological approach with substantially stronger evidence. The American Gastroenterological Association's 2024 guideline recommends pharmacotherapy as first-line for adults with a BMI of 30 or above, or 27 or above with weight-related comorbidities [17].

CGM platforms and GLP-1 therapy are not mutually exclusive. Some patients use both: CGM data to optimize food choices while titrating a GLP-1 medication. Signos itself began offering GLP-1 prescriptions through affiliated prescribers in 2024, blurring the line between its original CGM-only model and the broader telehealth weight-loss market.

What Does Signos Prescribe?

Signos expanded beyond CGM-only coaching to include prescription options through its affiliated telehealth network.

GLP-1 Medications

Through its medical partners, Signos can support prescriptions for semaglutide (both branded Wegovy and compounded formulations) and, where available, tirzepatide. Eligibility requires a BMI of 30 or above (or 27 with comorbidities), consistent with FDA labeling for these medications [18].

The CGM Sensor Itself

The CGM sensor requires a prescription in the United States. Signos facilitates this through its platform by connecting users with licensed prescribers who authorize the CGM order. This is a standard workflow shared by all direct-to-consumer CGM companies.

What Signos Does Not Prescribe

Signos does not prescribe insulin, metformin, or other diabetes medications. It does not manage diabetes treatment. If a CGM reveals glucose patterns consistent with undiagnosed type 2 diabetes (fasting glucose of 126 mg/dL or above, or random glucose above 200 mg/dL with symptoms), the user should be referred to their primary care physician or endocrinologist for formal diagnosis and management [4].

Making a Decision: A Clinical Framework

The question is not whether Signos "works." The question is whether it works for you, given your metabolic profile and goals.

Consider Signos If You

• Have prediabetes (HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dL) and want to understand your personal glucose triggers
• Have a BMI of 27 or above and have not responded to calorie-counting or macronutrient-tracking approaches
• Are curious about individual food responses and are willing to invest $200-$400/month for 3 to 6 months of data
• Are already on a GLP-1 medication and want to optimize your dietary choices alongside pharmacotherapy

Skip Signos If You

• Have a BMI under 25 with normal glucose markers
• Have a history of disordered eating or obsessive food tracking
• Are looking for significant weight loss (>10% body weight) and are not concurrently using pharmacotherapy
• Cannot commit to the subscription cost for at least 3 months (shorter durations may not provide enough data for behavior change)

The Diabetes Prevention Program (DPP) trial demonstrated that structured lifestyle intervention reduced diabetes incidence by 58% over 2.8 years in prediabetic adults (N=3,234), with a mean weight loss of 7% [19]. That intervention cost significantly less than a CGM subscription and remains the gold-standard comparison for any lifestyle-based metabolic health program.